Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $60.8 million.

  • Theravance Biopharma's Non-Current Assets fell 7464.25% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $506.9 million, marking a year-over-year decrease of 4815.85%. This contributed to the annual value of $193.1 million for FY2024, which is 2228.3% down from last year.
  • As of Q3 2025, Theravance Biopharma's Non-Current Assets stood at $60.8 million, which was down 7464.25% from $59.7 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Non-Current Assets ranged from a high of $277.2 million in Q1 2023 and a low of $37.7 million during Q4 2021
  • Moreover, its 5-year median value for Non-Current Assets was $206.0 million (2022), whereas its average is $181.7 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 57365.96% in 2022, then plummeted by 7538.71% in 2025.
  • Theravance Biopharma's Non-Current Assets (Quarter) stood at $37.7 million in 2021, then surged by 573.66% to $253.9 million in 2022, then dropped by 2.16% to $248.5 million in 2023, then decreased by 22.28% to $193.1 million in 2024, then crashed by 68.53% to $60.8 million in 2025.
  • Its Non-Current Assets was $60.8 million in Q3 2025, compared to $59.7 million in Q2 2025 and $193.3 million in Q1 2025.